SUBSCRIBE
SUBSCRIBE

Nick Paul Taylor

Nick is a freelance writer who has been reporting on the global life sciences industry since 2008. With a BSc in biology, Nick writes about the science and business of biopharma and medtech for numerous healthcare publications. He can be reached at nick.paul.taylor@gmail.com or on LinkedIn.

FDA signage at its headquarters in Maryland
Manufacturing
FDA’s PreCheck Proposal a Welcome But Insufficient Step, Company Execs Say
While a new facility setup program aimed at encouraging onshoring received a positive reception at a recent meeting, industry representatives said the current rules on existing production plants are the main regulatory issues facing manufacturing teams.
October 14, 2025
 · 
4 min read
 · 
Nick Paul Taylor
Close up of set of a playing cards
Manufacturing
AMT Designation Takes First Steps Amid Uncertain Benefits
Cell and gene therapy experts question where the FDA designation fits in an environment that features a range of intersecting regulatory perks.
October 7, 2025
 · 
5 min read
 · 
Nick Paul Taylor
Victoria Tower Houses of Parliament Westminster Bridge Night Stars London England. Built in the 1800s, House of Commons and House of Lords.
Government
How the UK’s ‘Credibility Challenge’ Hinders Attempts To Reverse Pharma’s Flight
Talks between pharma and successive U.K. governments have failed to deliver the market access terms that the industry wants, contributing to a pullback in investment.
October 1, 2025
 · 
4 min read
 · 
Nick Paul Taylor
Close-up of medical ampoule production line/iStock
Manufacturing
Drug Manufacturers See Long-Term Opportunity in Climbing AI Use
Companies are moving from using AI for distinct operations to applying the technology for control and optimization of the whole production process.
September 30, 2025
 · 
4 min read
 · 
Nick Paul Taylor
Pictured: Weight loss scale and pile of money/Tayl
Manufacturing
To Compete in Obesity, Late Entrants Invest Early in Manufacturing
Small and large drugmakers alike have made big, proactive moves to secure the production capacity that will be vital to serving the weight loss market.
September 23, 2025
 · 
5 min read
 · 
Nick Paul Taylor
map of United States of America with medicine pills and white background
Manufacturing
Trump’s Reshoring Drive Raises Questions About Supply Resilience
Some observers see risks to becoming over-reliant on local facilities, noting the potential need for trade partners if domestic production is disrupted.
September 16, 2025
 · 
4 min read
 · 
Nick Paul Taylor
Business vision and target. Businessman holding telescope standing on arrow up go to success in career. Concept business, Achievement, Character, Leader, Vector illustration flat
Obesity
Beyond MariTide: Amgen Makes Portfolio Play Amid Scrutiny of Obesity Prospect
Suddenly one obesity asset has come to define Amgen but executives see a fuller portfolio that will bring the big biotech into the future.
September 10, 2025
 · 
5 min read
 · 
Nick Paul Taylor
FDA recently approved BESREMi for the treatment of
Manufacturing
As Ori Wins Designation, FDA’s Advanced Manufacturing Program Nears Proof Point
Ori Biotech’s CEO said the prioritization of review by FDA, coupled to the impact of the technology, could shave up to three years off development timelines.
September 9, 2025
 · 
5 min read
 · 
Nick Paul Taylor
3d rendering of a plastic jar with medical pills on a hand truck on blue background. Medicine and health. Bottles and containers. Healthcare industry.
Manufacturing
Trump’s Push To Shore Up Pharma Supply Chain With US API Welcomed but Questioned
While trade groups hail the executive order as a national health security opportunity, analysts warn that production costs could go up in the near term.
September 2, 2025
 · 
4 min read
 · 
Nick Paul Taylor
a robotic assembly line with vials
Manufacturing
Drugmakers Hail Early Wins in AI-Driven Transformation of Manufacturing
Companies have claimed improvements to yield, batch consistency and output while acknowledging the risks and challenges created by the technology.
August 26, 2025
 · 
5 min read
 · 
Nick Paul Taylor
Hands in black and white dropping a collection of pills on a pink background
Manufacturing
Oral Wegovy’s Pending Approval Puts Spotlight on Viability of High-Dose Peptides
While the 10-fold increase in dose over injectable Wegovy has raised questions about the launch, Novo Nordisk has assured investors it has the manufacturing capacity to roll out oral semaglutide without restrictions on supply.
August 19, 2025
 · 
5 min read
 · 
Nick Paul Taylor
concept of a perilous situation with a man who finds himself suspended above the void while standing at the edge of the cliffs.
GLP-1
A Compounding Problem: How GLP-1s Drove Novo Nordisk’s Rapid Rise and Fall
Novo Nordisk has plummeted back to Earth after a stunning rise driven by Ozempic and Wegovy. Can the storied Danish pharma recover?
August 13, 2025
 · 
5 min read
 · 
Nick Paul Taylor
Isometric projection of a medieval castle on an island
Manufacturing
Obesity Leaders Dig Manufacturing Moats To Defend Injectable GLP-1 Empires
Leaders at Eli Lilly believe heavy investment in the company’s manufacturing footprint “sets a high standard that newcomers may find challenging to match.” At least one of those newcomers disagrees.
August 12, 2025
 · 
6 min read
 · 
Nick Paul Taylor
Biontech SE headquarters with company flags, German biotechnology company, BioNTech Manufacturing, development and production active immunotherapeutic agents in Mainz, Germany - September 7, 2024
Earnings
BioNTech Commits to Infectious Diseases Amid Questions Over Vaccine Demand
The company expects that the U.S. COVID-19 vaccination rate will be “maybe a couple of points lower” than the prior level of around 20% but that pricing and Comirnaty’s market share will hold steady.
August 4, 2025
 · 
2 min read
 · 
Nick Paul Taylor
Protection From Tariffs as an An umbrella that shields against import and export tariff taxes as a trade war storm increasing prices and straining supply chains as a business metaphor and a symbol for resilience in times of crisis and economic downturn.
Earnings
Sanofi Confident Tariffs Will Have Limited Impact on Finances in 2025
For now, Sanofi’s U.S. inventory is insulating the company from a potential 15% tariff on drugs shipped from the EU.
July 31, 2025
 · 
2 min read
 · 
Nick Paul Taylor
Load More